A Reinforcement Approach to Increase Use of CGM
研究概览
详细说明
The purpose of this pilot project is to evaluate the effectiveness of a behavioral economic intervention to increase use of continuous glucose monitors (CGM) in adolescents and young adults with T1D. This study will be done in conjunction with Nancy Petry, PhD and her research team at University of Connecticut School of Medicine (UConn Health). The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data. A 6-month pilot trial will be conducted with up to 20 patients receiving the intervention. The specific aims are:
- To estimate how well a reinforcement intervention increases usage of CGM. The proportion of days on which participants wear the CGM will be determined as well as the number of weeks during which CGM is worn at least 5 days. We will compare usage rates in the pilot trial to historical control data of patients initiating CGM.
- To evaluate the association between CGM usage and A1c. We expect A1c will decrease over time in patients who receive the reinforcement intervention. Patients who continue using the CGM are expected to have greater decreases in A1c than patients who discontinue its usage.
Evaluations will be conducted at time of CGM initiation, and 6, 13, 19, 26, and 39 weeks after treatment initiation to assess effects of the intervention and estimate effect sizes.
In addition to the primary aims, secondary outcomes will also be evaluated. Continued use of CGM is expected to improve aspects of diabetes management and daily functioning. Predictors of continued CGM usage and improvements in A1c will also be evaluated.
Results from this pilot study will be instrumental for guiding a subsequent, larger and longer term randomized study for evaluating reinforcement interventions for improving uptake of CGM, other diabetes-related adherence behaviors, and long-term outcomes.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- Yale University School of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- age 13-26 years old;
- diagnosis of type 1 diabetes (T1D) >12 months via ADA guidelines
- average A1c >7.5% and <14% during the year before study entry, and most recent A1c >7.5% but <14%;
- have ordered and received a CGM, but have not used a CGM >3 days a week on average during the past 6 months.
- test blood glucose levels at least 2 times per day on average;
- access to a computer with internet for uploading CGM data;
- access to a cell phone to communicate with research staff;
- English speaking, able to read at >5th grade level, and pass an informed consent quiz; and adequate knowledge of insulin dosing and dietary recommendations for managing T1D.
Exclusion Criteria:
- have a major psychiatric or neurocognitive disorder (e.g., severe learning impairment) that would inhibit participation;
- have a major visual impairment;
- have a significant other medical condition that impacts diabetes management (e.g., rheumatoid arthritis, or other condition that requires steroid treatment);
- plan to switch insulin delivery mode (injection to pump or vice versa) in the next 12 months, or have recently switched.
- Fail to complete the baseline phase wearing the CGM.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Reinforcement for wearing CGM
The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
|
The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in the Proportion of days participants wear the CGM
大体时间：up to 39 weeks
|
CGM data uploaded to a CGM tracking website (e.g., Dexcom CLARITY™, Carelink) will be used to calculate the change in the proportion of days when the patient wore the CGM.
At the 6, 13, 19, 26 and 39 week study visits, data will be uploaded and exported into an Excel file to calculate the days.
|
up to 39 weeks
|
|
Change in the number of weeks participants wear the CGM on at least 5 days
大体时间：up to 39 weeks
|
CGM data uploaded to a CGM tracking website (e.g., Dexcom CLARITY™, Carelink) will be used to calculate the change in the number of weeks when the CGM is worn at least 5 days.
At the 6, 13, 19, 26 and 39 week study visits, CGM data will be uploaded and exported into an Excel file to calculate the number of weeks when it is worn at least 5 days.
|
up to 39 weeks
|
|
Change in A1c
大体时间：up to 39 weeks
|
Change in A1c will be evaluated at the week 6, 13, 19, 26 and 39 week study visits by finger prick (DCA Vantage,Siemons).
|
up to 39 weeks
|
合作者和调查者
调查人员
- 首席研究员：William Tamborlane, MD、Yale University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
1 型糖尿病的临床试验
-
Oxford Brookes UniversityUniversity of Oxford完全的体力活动 | 心理健康 1 | 认知功能 1，社交 | Academic Attainment | Fitness Testing英国
-
Merck Sharp & Dohme LLC招聘中非小细胞肺癌 | 实体瘤 | 程序性细胞死亡-1（PD1、PD-1） | 程序性细胞死亡 1 配体 1(PDL1, PD-L1) | 程序性细胞死亡 1 配体 2（PDL2、PD-L2）日本
-
Amsterdam UMC, location VUmcRadboud University Medical Center; Maastricht University Medical Center; GGZ inGeest; Neurocare; M... 和其他合作者招聘中
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical Solution完全的